KR100661081B1 - 6-Methylnicotinamide derivatives as antiviral agents - Google Patents

Abstract

The present invention relates to a novel 6-methylnicotinamide derivative useful as an antiviral agent, a preparation method thereof, and a pharmaceutical composition comprising the same. Specifically, the 6-methylnicotinamide derivative represented by the following Chemical Formula 1, which is a non-nucleic acid compound, is HBV. As well as the growth of Hepatitis B Virus and HCV (Hepatitis C virus) as well as inhibiting the growth of Human Immunodeficiency Virus (HIV), it can be useful as a treatment and prevention of hepatitis B, hepatitis C and AIDS. have.

In Formula 1, R and n are as described in the specification.

Description

6-Methylnicotinamide derivatives as antiviral agents}             

The present invention relates to a 6-methylnicotinamide derivative useful as an antiviral agent, and more particularly, a novel 6-methylnicotinamide derivative represented by the following Chemical Formula 1 having excellent inhibitory effect on HBV, HCV and HIV, and a pharmaceutical thereof The present invention relates to a salt, a preparation method thereof, and an antiviral pharmaceutical composition comprising the compound as an active ingredient.

Formula 1

In Chemical Formula 1,

R represents a C ₁ -C ₅ straight or crushed alkyl group, a C ₃ -C ₆ cycloalkyl group substituted or unsubstituted with a hydroxy group, or a saturated or unsaturated 5 or 6 membered heterocycle, wherein hetero The ring contains 1 to 2 heteroatoms selected from N, O and S, and n is an integer of 0 to 3, inclusive.

Hepatitis B virus (HBV; hereinafter referred to as "HBV") is a pathogen that causes chronic or acute hepatitis and worsens liver cirrhosis and liver cancer. It is estimated (Tiollais & Buendia, Sci. Am. , 264, 48, 1991). Therefore, for the purpose of treatment and prevention of hepatitis B, many studies have been conducted on the relationship between HBV and liver disease, including molecular biological characteristics of HBV, and various vaccines and diagnostic reagents for hepatitis B have been developed. In addition, efforts are underway to develop treatments for hepatitis B.

The genome of HBV is polymerase gene (P; polymerase), surface antigen gene (S; surface protein; pre-S1, pre-S2, S), central antigen gene (C; core protein; pre-C, C), X It consists of four genes, including the protein gene. Among them, polymerase, surface antigen, and central antigen genes express structural proteins, and X protein genes are known to express regulatory proteins.

The HBV polymerase gene accounts for 80% of the entire viral genome and produces a 94kD protein consisting of 845 amino acids, which contains a set of functions necessary for the replication of the viral genome. Ie) protein primer, ii) RNA dependent DNA polymerase (RT), iii) DNA dependent DNA polymerase (DDDP), and Enzyme (RNase H) function and the like are present in one polypeptide. Kaplan et al. Described the reverse transcription activity of polymerase protein for the first time, and many studies on the replication mechanism of HBV have been made.

In HBV, surface antigen proteins outside the virion are recognized by hepatocyte-specific receptors and enter into the hepatocytes. At this time, the rest of the incomplete double-stranded DNA is synthesized by HBV polymerase activity, and the HBV DNA genome is synthesized. Is completed. The completed HBV DNA genome produces mRNAs such as pre-genomic mRNAs, central antigens (C), surface antigens (S), and regulatory proteins (X) by intracellular RNA polymerase activity. Viral proteins are made from these mRNAs, and in particular, polymerase proteins play a role in synthesizing the viral genome and form structures called replicatics with central antigen proteins and genome mRNAs. This is called encapsidation, and the polymerase protein is easily encapsidated by nucleic acid affinity at a site where glutamic acid is repeated at the 3′-end. When a replicasome is formed, (-) DNA chain is synthesized by reverse transcription activity of HBV polymerase protein, and (+) DNA chain is synthesized by DNA dependent DNA polymerase activity, which in turn produces genome mRNAs. This repetition maintains more than 200 to 300 genomic DNA pools in the cell (Tiollais and Buendia, Scientific American , 264: 48-54, 1991).

HBV and HIV are different kinds of viruses, but they have a common replication process. That is, the reverse transcription process in which transcription from viral RNA to DNA is performed and the process of decomposing and erasing the RNA portion of the RNA-DNA hybrid generated by reverse transcription is common.

HBV inhibitors of nucleic acid-based compounds, such as lamivudine and famvir, which have recently been developed as treatments for Acquired Immune Deficiency Syndrome (AIDS) or shingles infection As usefulness (Gerin J. L, Hepatology , 14: 198-199, 1991; Lok A. .SP, J. Viral Hepatitis , 1: 105-124, 1994; Dienstag, JL et al ., New England Journal of Medicine , 333: 1657-1661, 1995). However, these nucleic acid-based compounds are very expensive and put a high economic burden on patients, and furthermore, since nucleic acid-based compounds inherently have serious problems in side effects such as toxicity, emergence of resistant virus and relapse after discontinuation of drug administration. It is known that it is unsuitable as a hepatitis agent. Therefore, efforts have been made to develop a hepatitis B therapeutic agent among non-nucleosides compounds, and quinolone compounds having antiviral activity against HBV (European Patent Nos. 563732 and 563734), iridoid compounds (Korean Patent Publication No. 94-1886) and terephthalic acid amide derivatives (Korean Patent Application Nos. 96-72384, 97-36589, 99-5100) and the like have been reported. However, despite many efforts, no clear treatment for hepatitis B has been developed so far, and the treatment of hepatitis B is mainly dependent on symptomatic therapy.

Hepatitis C virus (HCV; hereinafter referred to as "HCV") is a membraned virus belonging to the Flavivirus family. The genome is (+)-RNA (plus-strand RNA), which is 9.5 kb in size and expresses a polyprotein consisting of 3,010 amino acids. This polyprotein is separated into three structural proteins and six nonstructural proteins by enzymes of the host cell and virus.

At the 5 'and 3' ends of the HCV genome, there are non-toxic sites where the base sequences of almost all genotypes remain the same. Recently, 330-341 nucleotides at the 5 'end and 98 nucleotides after the poly A at the 3' end have recently been found, which is believed to play an important role in viral RNA replication or translation. The amino terminus of the viral genome produces the central antigen genes (Core), E1 and E2, which are viral structural proteins, and the rest of the viral genome produces nonstructural proteins. The central antigen gene consists of the virus's capsid protein, E1 and E2, the virus's envelope proteins, which are separated by signal peptidase in the endoplasmic reticulum. Nonstructural proteins are separated by the serine protease NS3 and the cofactor NS4A. NS5B has RNA-dependent RNA polymerase function and is the most important enzyme for viral replication.                         

Infection with HCV is caused by transfusion and community-acquired, and about 70% of infections are reported by kidney dialysis. About 20% of HCV infections cause acute hepatitis with cirrhosis within 5 years and spread to liver cancer. This high rate of chronic infection is rare in RNA viruses, demonstrating that HCV is a mediator of high rates of liver cancer. The mechanism of persistent infection of HCV has not been studied. In recent years, all blood has been well tested for HCV infection, and infection due to blood transfusion has been significantly reduced. However, community-acquired HCV infection has not yet been controlled, and has emerged as an important problem worldwide.

Epidemiologically, HCV, unlike HBV, is evenly distributed throughout the world, with 1.5 to 2% of the world's population infected. HCV infection is characterized by progression to chronic hepatitis, which is more likely than hepatitis B to liver cirrhosis and liver cancer. Because type C belongs to a class of viruses that is completely different from type B, it is impossible to prevent with type B vaccine. Attempts have been made to treat α-interferon, but the response varies considerably and genotypes are very minimal.

Many studies have been conducted since HCV was discovered in 1987, but no effective treatment has been developed. Currently, only interferon is used, but the treatment rate is less than 30%, and it has been confirmed that a mutation virus that recurs upon discontinuation and is resistant to interferon occurs. Therefore, no development has been developed as a specific growth inhibitor for HCV.

On the other hand, AIDS is a disease that spreads throughout the body due to the distinctly low cellular immune function of the body, which is not seen in ordinary people, and is the main attack of HIV (Human Immunodeficiency Virus, or "HIV"). The goal is known to be helper T cells, one of the T cells that regulate immune function. When secondary T cells become infected by HIV and cause necrosis, the body's immune function is not functioning properly, resulting in an immunodeficiency condition, which causes fatal infections and malignant tumors. Since it was first discovered in the United States in 1981, more than 850,000 people have been reported in 187 countries in 1993 (the World Health Organization's late 1993 report). Furthermore, the World Health Organization reports that by 2000, 30 million to 40 million more will be infected and 10 million to 20 million of them will develop.

Drugs that inhibit the proliferative process of HIV are currently the most widely used in the treatment of AIDS, including Zidovudine (ZDV), formerly named Azidothymidine (AZT), which was first developed in 1987, and have side effects or treatment effects Alternative medicines include Didanosine (ddI), developed in 1991, and Zalcitabine (ddC), licensed for use in combination with zidovudine in 1992. These drugs have the effect of alleviating the symptoms of AIDS patients, slowing the transition of HIV infected people to AIDS, or slightly extending their survival. However, there is no cure and resistance and side effects are a problem.

Accordingly, the present inventors have tried to develop a non-nucleic acid compound exhibiting excellent antiviral activity against HBV for the purpose of developing a novel hepatitis B treatment agent with low side effects, low toxicity, and low resistance virus. The 6-methylnicotinamide derivative of was synthesized, and the present invention was completed by revealing that the substance was excellent in inhibiting HBV growth, as well as in inhibiting HCV growth and HIV growth.

It is an object of the present invention to provide novel 6-methylnicotinamide derivatives, pharmaceutically acceptable salts thereof and methods for their preparation.

It is also an object of the present invention to provide a pharmaceutical composition for the treatment and prevention of hepatitis B and hepatitis C and AIDS, with the compound as an active ingredient and less side effects and economical.

In order to achieve the above object, the present invention provides a novel 6-methylnicotinamide derivative represented by the following formula (1) and a pharmaceutically acceptable salt thereof.                     

Formula 1

In Chemical Formula 1,

R represents a C ₁ -C ₅ straight or crushed alkyl group, a C ₃ -C ₆ cycloalkyl group substituted or unsubstituted with a hydroxy group, or a saturated or unsaturated 5 or 6 membered heterocycle, wherein hetero The ring contains 1 to 2 heteroatoms selected from N, O, S,

n is an integer of 0-3.

Preferably in Formula 1,

R is an isopropyl group, 4-morpholinyl group, 4-hydroxy-1-cyclohexyl group, 3-pyridyl group, 2-pyridyl group, n is an integer of 0-2.

More preferable compounds among the compounds of the present invention are as follows.

2- ( 1H -5-indazolylamino) -N -isopropyl-6-methylnicotinamide

2- ( 1H -5-indazolylamino) -6-methyl- N- (4-morpholinyl) -nicotinamide

N- (trans-4-hydroxy-1-cyclohexyl) -2- ( 1H -5-indazolylamino) -6-methylnicotinamide

2- ( 1H -5-indazolylamino) -6-methyl- N- (3-pyridyl) -nicotinamide

2- ( 1H -5-indazolylamino) -6-methyl- N- (3-pyridylmethyl) -nicotylamide

2- (1H-5-indazolylamino) -6-methyl- N- (3-pyridylethyl) -nicotylamide

The compound of the present invention exhibits the effect of inhibiting HIV proliferation as well as proliferation of HBV and HCV by having 5-indazolylamino group as a substituent in 6-methylnicotinamide derivative.

The compound of formula 1 of the present invention may be used in the form of a pharmaceutically acceptable salt, and as the salt, an acid addition salt formed by a pharmaceutically acceptable free acid is useful. Compounds of formula (1) may form pharmaceutically acceptable acid addition salts according to methods conventional in the art. Organic acids and inorganic acids may be used as the free acid, hydrochloric acid, bromic acid, sulfuric acid, phosphoric acid, etc. may be used as the inorganic acid, and citric acid, acetic acid, lactic acid, tartaric acid, maleic acid, and fumaric acid may be used as the organic acid. (fumaric acid), formic acid, propionic acid, oxalic acid, trifluoroacetic acid, benzoic acid, gluconic acid, methanesulfonic acid, glycolic acid, succinic acid, 4-toluenesulfonic acid, galluxuronic acid, embonic acid, glutamic acid or aspartic acid Can be used.

In addition, the present invention provides a method for preparing a 6-methylnicotinamide derivative represented by the following formula (1).

In Scheme 1, R and n are as defined in formula (1).

The manufacturing method of the present invention

1) 2-Chloro-6-methylnicotinic acid (2) and 5-aminoindazole (3) were heated in the presence of a base to give 2- ( 1H -5-indazolylamino) -6-methylnicotinic acid (4). Preparing step (step 1); And

2) activating the compound (4) prepared in step 1, followed by reacting with an amine compound (5) having an appropriate substituent to prepare a 6-methylnicotinamide derivative of formula (Step 2).

2-chloro-6-methylnicotinic acid (2), 5-aminoindazole (3) and amine compound (5) used as starting materials and reactants in steps 1 and 2 are readily available as commercially available materials. Can be purchased and used.

In addition, the amine compound (5) of step 2 is a substance for introducing a substituent [-NH- (CH ₂ ) _n -R] to the target compound of the formula (1), select an appropriate amine compound (5) according to the type of substituent It can be easily selected and used by those of ordinary skill in the art.

When explaining step 1 in more detail, as a base may be used a tertiary organic base that is not very basic, for example, pyridine, picoline, lutidine, N, N- dimethylaniline, 4-dimethylaminopyridine and the like Preference is given to using the same organic base.

In addition, the step 2 will be described in more detail. The reaction is carried out with thionyl chloride (SOCl ₂ ) at a temperature range of 30 to 50 ° C. to activate an acid chloride, or thionyl chloride and N, N -dimethylformamide (DMF). ) Was heated to synthesize the Vilsmeier Reagent, which was used to activate 2- (1 H -5-indazolylamino) -6-methylnicotinic acid (4), and then at a temperature of 0 to 20 ° C. The desired compound of formula 1 is prepared by reacting with an amine compound (5) having an appropriate substituent of the invention.

At this time, as a reaction solvent, an aprotic solvent which cannot dissociate protons is preferable, and for example, chloroform, methylene chloride, acetonitrile, tetrahydrofuran, ether, or a mixed solvent thereof is preferably used. Do.

The present invention also provides a pharmaceutical composition for the treatment or prophylaxis of hepatitis B, comprising 6-methylnicotinamide derivative of Formula 1 and / or a pharmaceutically acceptable salt thereof as an active ingredient.

The present invention also provides a pharmaceutical composition for the treatment or prophylaxis of hepatitis C, comprising 6-methylnicotinamide derivative of Formula 1 and / or a pharmaceutically acceptable salt thereof as an active ingredient.

RNA-dependent RNA-polymerase inhibitors of HCV will ultimately be able to inhibit the proliferation of HCV and also because RNA-dependent RNA polymerase has not yet been found in human cells. The compound is expected to be a hepatitis C treatment with fewer side effects.

The 6-methylnicotinamide derivative represented by the general formula (1) of the present invention is a replication process that is common in the proliferation process of HBV and HIV, that is, reverse transcription from viral RNA to DNA, and the RNA portion is degraded in the resulting RNA-DNA hybrid. It has a mechanism of action that inhibits the process, and has proliferation inhibitory activity against HIV as well as HBV.

Accordingly, the present invention provides a pharmaceutical composition for treating or preventing AIDS, comprising 6-methylnicotinamide derivative of Formula 1 and / or a pharmaceutically acceptable salt thereof as an active ingredient.

The compound of formula 1 may be administered orally or parenterally, for example, intravenously, subcutaneously, intraperitoneally or topically, during clinical administration and may be used in the form of general pharmaceutical formulations.

Clinical use of the pharmaceutical composition of the present invention may be combined with a conventional carrier in the pharmaceutical field for oral administration of a conventional agent in the pharmaceutical field, for example, tablets, capsules, troches, solutions, suspensions, and the like. Formulations; It may be formulated into a variety of preparations, such as injectable solutions or suspensions, or injectable preparations in the form of ready-to-use injectable dry powders that can be prepared and used as injectable distilled water at the time of injection.

The effective dose of the compound of formula 1 is generally 10-500 mg / kg in adults, preferably 50-300 mg / kg, several times a day at a predetermined time interval, preferably one day, at the discretion of the doctor or pharmacist. It may be administered in 1 to 6 divided doses.

Hereinafter, the present invention will be described in more detail with reference to Examples.

However, the following examples are illustrative of the present invention, and the content of the present invention is not limited by the examples.

Production Example 1 2- (1 H Preparation of -5-indazolylamino) -6-methylnicotinic acid

To 70 ml of methanol, 10 g of 2-chloro-6-methylnicotinic acid, 8.6 g of 5-aminoindazole and 10 ml of pyridine were sequentially added, followed by reaction at 40 to 50 ° C. for 3 days. The reaction mixture was cooled and slowly added 35 ml of water at 20 ° C. and stirred for 2 hours, then filtered and the resulting crystals washed with 15 ml of 50% methanol. The obtained crystals were vacuum dried at 40 to 50 ° C. to obtain 13 g (yield 83%) of the title compound.

m.p. : 252 to 254 ° C

¹ H-NMR (DMSO-d ₆ ), ppm: δ 2.40 (s, 3H), 6.66 (d, 1H), 7.41 (m, 2H), 7.96 (d, 1H), 8.09 (d, 1H), 8.31 (q, 1H), 10.42 (s, 1H), 13.13 (br S, 2H)

Example 1 2- (1 H -5-indazolylamino)- N- Preparation of Isopropyl-6-methylnicotinamide

2.3 ml of N, N -dimethylformamide and 2.7 ml of thionyl chloride were added to 120 ml of methylene chloride and heated to reflux for 2 hours, followed by 2- ( 1H -5-indazolylamino) -prepared in Preparation Example 1 4 g of 6-methylnicotinic acid was added and refluxed for 2 hours. The reaction was cooled and 6 ml of isopropylamine was slowly added at 0-5 ° C. and stirred for 1 hour. And filtered and then added to aqueous sodium hydroxide solution adjusted to pH = 9-10 and stirred at 20 ℃ for 30 minutes was concentrated under reduced pressure, the solvent was dissolved in methanol 50 ㎖ to the residue water and 50 ㎖ 3 N. The resulting solid was recrystallized from a 1: 10 mixed solvent of chloroform and isopropyl ether to obtain 3.6 g (yield 78%) of the title compound.

m.p. : 203 ~ 206 ℃

¹ H-NMR (DMSO-d ₆ ), ppm: δ 1.17 (d, 6H), 2.40 (s, 3H), 4.12 (m, 1H), 6.65 (d, 1H), 7.35 (d, 1H), 7.43 (d, 1H), 7.96 (s, 1H), 8.00 (d, 1H), 8.34 (d, 2H), 11.01 (s, 1H), 12.89 (s, 1H)

Example 2 2- (1 H -5-indazolylamino) -6-methyl- N- Preparation of (4-morpholinyl) -nicotinamide

To 30 ml of methylene chloride , 0.34 ml of N, N -dimethylformamide and 0.4 ml of thionyl chloride were added and heated to reflux for 2 hours, followed by 2- ( 1H -5-indazolylamino) -prepared in Preparation Example 1 0.6 g of 6-methylnicotinic acid was added and refluxed for 2 hours. The reaction was cooled and 1 ml of 4-aminomorpholine was added at 0-5 ° C. and stirred for 1 hour. The solvent was concentrated under reduced pressure, and 20 ml of water and 3 N -sodium hydroxide aqueous solution were added to the residue to adjust the pH to 9-10, followed by extraction with 30 ml of chloroform. The organic layer was concentrated under reduced pressure, and the residue was purified by column chromatography (chloroform: isopropanol = 10: 1 (volume ratio)), concentrated under reduced pressure, and crystallized with ether to obtain 0.45 g (yield 57%) of the title compound.

m.p. : 257 to 260 ° C                     

¹ H-NMR (DMSO-d ₆ ), ppm: δ 2.40 (s, 3H), 2.87 (br s, 4H), 3.66 (br s, 4H), 6.65 (d, 1H), 7.35 (d, 1H ), 7.44 (d, 1H), 7.91 (d, 1H), 7.97 (s, 1H), 8.33 (s, 1H), 9.63 (s, 1H), 10.66 (s, 1H), 12.90 (s, 1H)

<Example 3> N -(Trans-4-hydroxy-1-cyclohexyl) -2- (1 H Preparation of -5-indazolylamino) -6-methylnicotinamide

To 20 ml of methylene chloride , 0.23 ml of N, N -dimethylformamide and 0.27 ml of thionyl chloride were added and heated to reflux for 2 hours, followed by 2- ( 1H -5-indazolylamino) -prepared in Preparation Example 1 0.4 g of 6-methylnicotinic acid was added and refluxed for 2 hours. The reaction was cooled and slowly added 0.7 g of trans-4-aminocyclohexanol hydrochloride and 0.8 ml of triethylamine at 0-5 ° C. and stirred for 1 hour. The solvent was concentrated under reduced pressure, 7 ml of methanol and 12 ml of water were added to the residue, the mixture was adjusted to pH = 10 with 3 N aqueous sodium hydroxide solution, stirred at 20 ° C. for 30 minutes, filtered, and washed with water. The obtained solid was recrystallized one by one with methanol and methylene chloride one by one to obtain 0.35 g (yield 64%) of the title compound.

m.p. :> 280 ℃

¹ H-NMR (DMSO-d ₆ ), ppm: δ 1.19 (m, 2H), 1.32 (m, 2H), 1.80 (m, 4H), 2.39 (s, 3H), 3.38 (d, 1H), 3.86 (br s, 1H), 4.58 (d, 1H), 6.64 (q, 1H), 7.35 (d, 1H), 7.43 (m, 1H), 7.96 (m, 2H), 8.28 (t, 2H), 10.96 (d, 1 H), 12.90 (s, 1 H)

Example 4 2- (1 H -5-indazolylamino) -6-methyl- N Preparation of-(3-pyridyl) -nicotinamide

Using 3-aminopyridine instead of 4-aminomorpholine was synthesized and purified in the same manner as in Example 2 to obtain 53% of the title compound.

m.p. : 237 ~ 240 ℃

¹ H-NMR (DMSO-d ₆ ), ppm: δ2.44 (s, 3H), 6.76 (d, 2H), 7.39 (m, 3H), 7.98 (s, 1H), 8.12 (d, 1H), 8.18 (q, 1H), 8.31 (t, 2H), 8.87 (s, 1H), 10.47 (s, 1H), 12.92 (s, 1H)

Example 5 2- (1 H -5-indazolylamino) -6-methyl- N Preparation of-(3-pyridylmethyl) -nicotinamide

Synthesis and recrystallization in the same manner as in Example 1 using 3- (aminomethyl) pyridine instead of isopropylamine to obtain the target compound.

m.p. : 95-97 ℃

¹ H-NMR (DMSO-d ₆ ), ppm: δ 2.40 (s, 3H), 4.50 (br s, 2H), 6.69 (d, 1H), 7.30 (m, 3H), 7.74 (s, 1H) , 7.96 (s, 1H), 8.05 (d, 1H), 8.32 (s, 1H), 8.46 (s, 1H), 8.57 (s, 1H), 9.23 (s, 1H), 10.94 (s, 1H), 12.93 (s, 1 H)

Example 6 2- (1 H -5-indazolylamino) -6-methyl- N Preparation of-(2-pyridylethyl) nicotinamide

Synthesis was carried out in the same manner as in Example 2, using 2- (2-aminoethyl) pyridine instead of 4-aminomorpholine, and column chromatography (hexane: ethyl acetate: methanol = 5: 5: 1 (volume ratio)) After purification with crystallization with isopropyl ether to give the title compound of 73%.

m.p. : 98-99 ℃

¹ H-NMR (DMSO-d ₆ ), ppm: δ 2.40 (s, 3H), 3.02 (br s, 2H), 3.62 (br s, 2H), 6.65 (d, 1H), 7.20 (d, 1H ), 7.28 (d, 1H), 7.36 (d, 1H), 7.44 (d, 1H), 7.68 (t, 1H), 7.92 (d, 1H), 7.94 (s, 1H), 8.33 (s, 1H) , 8.49 (s, 1H), 8.74 (s, 1H), 10.96 (s, 1H), 12.90 (s, 1H)

Experimental Example 1 Inhibitory Effect of In Vitro Reverse Transcription Activity on HBV Polymerase

In order to determine the effect of the compounds of Formula 1 inhibit the reverse transcription activity of HBV polymerase, the following in vitro experiment was performed.

The present inventors have already filed a patent for a recombinant polymerase protein of HBV expressed in E. coli, a method for preparing the same, and a method for measuring the enzyme activity thereof (Korean Patent Application Nos. 94-3918 and 96-33998). In this experiment, HBV polymerase expressed in E. coli was used as described above.                     

The method for measuring reverse transcriptase activity of hepatitis B virus polymerase in vitro used in the present invention is as follows. The basic principle is the same as the enzyme-immunological method (ELISA), in which the nucleotides modified with biotin- and DIG- (digoxigenin-) are reacted with the substrate, and then the polymerized substrate with the anti-peroxidase The method of recognizing with -DIG antibody was used.

20 μl of HBV polymerase was added to a well coated with streptavidin and the reaction mixture [10 μM each of DIG-UTP, Biotin-UTP, 46 mM Tris-HCl, 266 mM KCl, 27.5 mM MgCl ₂ , 9.2 mM DTT substrate / primer hybrid] 20 µl and 20 µl of the test substance (addition of 1, 0.1 and 0.01 µg / ml, respectively) were mixed and reacted at 22 ° C for 15 hours. At this time, DNA is produced by the action of HBV polymerase and contains nucleotides attached with digoxigenin and biotin, which binds to streptavidin coated on the bottom of the well. After the reaction was completed, washed 5 times 30 seconds with 250 μl of wash buffer (pH 7.0) per well to remove the remaining impurities. After 200 μl of anti-DIG-POD antibody was added to each well and reacted at 37 ° C. for 1 hour, each well was washed with a washing buffer to remove impurities. Thereafter, 200 μl of ABTS ™, a substrate of POD (peroxidase), was added thereto, and the mixture was reacted at room temperature for 30 minutes, and the absorbance at 405 nm was measured using an ELISA reader.

The inhibition rate for reverse transcription activity of HBV polymerase was calculated based on the control group without the test compound, and the results are shown in Table 1 below.

Inhibitory Effect on Reverse Transcriptase Activity of HBV Polymerase Test compound % Inhibition of activity of HBV-RT 1 μg / ml 0.1 μg / ml 0.01 μg / ml Example 1 78 49 30 Example 2 88 57 42 Example 3 80 61 53 Example 4 92 64 50 Example 5 65 43 37 Example 6 84 55 40

As can be seen in Table 1 , the compounds of the present invention have a very good effect of inhibiting the activity of HBV polymerase, such as up to 92% of the activity inhibition rate for HBV polymerase at a concentration of 1 ㎍ / ㎖. In addition, since the compounds of the present invention are non-nucleic acid-based materials, it is expected to solve problems such as the early appearance of toxic and resistant viruses possessed by nucleic acid-based materials, and they may be used in combination with nucleic acid-based materials because they have different mechanisms of action. It can also be used as a therapy.

As described above, the compounds of the present invention have an excellent effect of inhibiting the activity of HBV polymerase, which plays an important role in the replication of HBV. Therefore, the compounds of the present invention can inhibit the proliferation of HBV by this mechanism, and thus are useful as a prophylactic and therapeutic agent for hepatitis B. Can be used.

Experimental Example 2 In Vitro Inhibitory Effect on HCV RNA-dependent RNA Polymerase

In order to determine the effect of the compounds of Formula 1 inhibit the activity of HCV RNA-dependent RNA polymerase, the following in vitro experiment was performed.

The method for measuring the activity of HCV RNA dependent RNA polymerase in vitro used in the present invention is as follows.

First, 10 μl of HCV NS5B (RNA polymerase) was added to a well coated with streptavidin, and the reaction buffer [Tris.Cl (pH 7.5) 0.25M, NaCl 0.25M, MgCl ₂ 0.025M _, KCl 0.25M, EDTA 0.005M , DTT 0.05M] 25 μl was added and the reaction mixture containing HCV 3'UTR- "X" RNA and DIG- (digoxigenin) -UTP, biotin-UTP, ATP, UTP, CTP, GTP as a template (reaction) 10 μl of the mixture was added, and 5 μl of the test substance (added so that the concentrations were 10, 1, and 0.1 μg / ml, respectively) was reacted at 22 ° C. for 1 hour. No sample was added to compare the activity as a negative control. At this time, RNA is produced by the action of HCV polymerase, and because it contains digoxygenin and biotin-attached nucleotides, the DNA binds to streptavidin coated on the bottom of the well. After the reaction, 200 μl of washing buffer (pH 7.0) was added to each well to remove the remaining impurities and washed three times for 30 seconds. After 200 μl of anti-DIG-POD antibody was added and reacted at 37 ° C. for 1 hour, each well was washed with a washing buffer to remove impurities. Subsequently, 200 μl of ABTS ^R , which is a substrate of POD, was added thereto, reacted at room temperature for 30 minutes, and the absorbance was measured at 405 nm using an ELISA reader.

The inhibition rate for reverse transcriptase activity of HCV RNA polymerase calculated based on the control without the test compound is shown in Table 2 below.

Inhibitory Effect on HCV RNA Polymerase Activity Test compound Inhibition Rate of HCV RNA Polymerase Activity (%) 10 μg / ml 1 μg / ml 0.1 μg / ml Example 1 59 38 12 Example 2 83 54 40 Example 3 90 61 46 Example 4 63 41 24 Example 5 52 37 10 Example 6 81 55 37

As can be seen in Table 2 , the compounds of the present invention is up to 90% of the activity inhibition rate for HCV polymerase at a concentration of 10 ㎍ / ㎖ and shows an inhibition rate of about 60% even at a concentration of 1 ㎍ / ㎖, HCV It can be seen that the effect of inhibiting the activity of the RNA polymerase is very excellent.

As described above, the compounds of the present invention have an excellent effect of inhibiting the activity of HCV RNA polymerase, which plays an important role in the replication of HCV. Therefore, the compounds of the present invention can suppress the proliferation of HCV, and thus are useful as a prophylactic and therapeutic agent for hepatitis C. Can be used. Furthermore, since the compounds of the present invention are non-nucleic acid-based materials, it is expected to solve problems such as the early appearance of toxic and resistant viruses possessed by nucleic acid-based materials, and they may be used in combination with nucleic acid-based materials because they have different mechanisms of action. It can also be used as a therapy.

Experimental Example 3 In Vitro Inhibitory Effect on HIV Reverse Transcriptase

In order to determine the effect of the compounds of Formula 1 inhibit the activity of HIV reverse transcriptase, the following in vitro experiments were carried out.

In vitro inhibitory activity was measured using a non-radioactive reverse transcriptase assay kit (Boehringer Mannheim).

20 μl (40 ng) of HIV reverse transcriptase was added to a well coated with streptavidin, and the template- primer hybrid poly (A) -oligo (dT) ₁₅ and DIG- (digoxygenin) -dUTP, biotin-dUTP, TTP After 20 µl of the reaction mixture containing the reaction mixture was added thereto, a test compound was added thereto to a final concentration of 0.1 and 1 µg / ml, and reacted at 37 ° C. for 1 hour. At this time, DNA is made from RNA by the action of HIV reverse transcriptase, and since digoxigenin and biotin are labeled together, streptavidin is coated on the bottom of the well. Will be combined.

After completion of the reaction, washing was performed 5 times for 30 seconds with 250 μl of washing buffer solution (pH 7.0) per well to remove remaining impurities. After washing, 200 μl of anti-DIG-POD antibody was added thereto and reacted at 37 ° C. for 1 hour, and the resultant was washed with the same buffer solution for washing to remove impurities. After washing, 200 μl of ABTS ™, a substrate of POD, was added to each well, followed by reaction at room temperature for 30 minutes. After completion of the reaction, the degree of inhibition of reverse transcriptase activity of HIV was quantified by measuring the absorbance at 405 nm of each solution using an ELISA reader. Inhibition rate for HIV reverse transcriptase activity was calculated based on the control without the test compound, the results are shown in Table 3 below.

Inhibitory Effect on HIV Reverse Transcriptase Activity Test compound HIV-RT activity inhibition rate (%) 1 μg / ml 0.1 μg / ml Example 1 75 42 Example 2 84 49 Example 3 80 51 Example 4 64 40 Example 5 69 38 Example 6 77 45

As can be seen in Table 3 , the compounds of the present invention have an inhibition rate of 84% or more against HIV-RT (HIV reverse transcriptase) at a concentration of 1 μg / ml and a inhibition rate of about 50% even at a concentration of 0.1 μg / ml. It can be seen that the effect of inhibiting the activity of HIV reverse transcriptase is excellent.

As described above, the compounds of the present invention have an excellent effect of inhibiting the activity of HIV reverse transcriptase, which plays an important role in reverse transcription of HIV replication. And therapeutic agents. In particular, since the compounds of the present invention are non-nucleic acid-based materials, it is expected to solve problems such as the toxicity of the nucleic acid-based materials and the early appearance of resistant viruses. In addition, since the nucleic acid-based materials act on the active domain of the polymerase, the compounds of the present invention are expected to act on the allosteric binding pocket, so the compounds of the present invention can be used as a combination therapy with nucleic acid-based materials. Can be.                     

Experimental Example 4 Cytotoxicity Test

In order to determine whether the compounds of Formula 1 exhibit cytotoxicity, in vitro experiments were carried out using HepG2 cells in a generally known MTT assay method.

As a result, all of the compounds used in the experiment were found to have a CC ₅₀ of 100 µg / ml or more, which is a very low toxicity to cells.

Experimental Example 5 Oral Acute Toxicity in Rats

In order to determine the acute toxicity of the compound of Formula 1 was performed the following experiment.

Acute toxicity experiments were performed using 6-week-old SPF SD rats. Six animals per group were suspended orally in a dose of 2 g / kg / 15 ml, each of the compounds of Examples 1-6 in 0.5% methylcellulose solution. After administration of the test substance, mortality, clinical symptoms, and changes in body weight were observed. Hematological and blood biochemical tests were performed. Necropsy was performed to visually check for abdominal and thoracic organ abnormalities. As a result, all animals treated with test substance showed no clinical symptoms and no dead animals, and no toxic changes were observed in weight change, blood test, blood biochemistry, autopsy findings. As a result, all of the tested compounds did not show toxic changes up to 2 g / kg in rats, and the minimum lethal dose (LD ₅₀ ) for oral administration was determined to be a safe substance of 2 g / kg or more.

As described above, the novel 6-methylnicotinamide derivative represented by the formula (1) according to the present invention is excellent in inhibiting the proliferation of HBV, HCV and HIV, and has fewer side effects, so hepatitis B and hepatitis C And prophylactic and therapeutic agents for AIDS. In particular, since the compounds of the present invention are non-nucleic acid-based materials, it is expected to solve problems such as early appearance of toxic and resistant viruses possessed by nucleic acid-based materials. In addition, since the nucleic acid compounds act on the active domain of the polymerase while the compounds of the present invention are expected to act on the allosteric binding pocket, the compounds of the present invention may be used as a combination therapy with nucleic acid compounds. have.

Claims (7)

6-methylnicotinamide derivative represented by the following formula (1) and pharmaceutically acceptable salts thereof. Formula 1

In Chemical Formula 1, R represents a C ₁ -C ₅ straight or crushed alkyl group, a C ₃ -C ₆ cycloalkyl group substituted or unsubstituted with a hydroxy group, or a saturated or unsaturated 5 or 6 membered heterocycle, wherein hetero The ring contains 1 to 2 heteroatoms selected from N, O, S, n is an integer of 0-3. The method of claim 1, R is isopropyl group, 4-morpholinyl group, 4-hydroxy-1-cyclohexyl group, 3-pyridyl group, 2-pyridyl group, n is 6-methylnicotinamide characterized in that it is an integer of 0-2. Derivatives and pharmaceutically acceptable salts thereof. According to claim 1, 6-methylnicotinamide derivative represented by the formula (1) 2- ( 1H -5-indazolylamino) -N -isopropyl-6-methylnicotinamide, 2- ( 1H -5-indazolylamino) -6-methyl- N- (4-morpholinyl) -nicotinamide, N- (trans-4-hydroxy-1-cyclohexyl) -2- (1 H -5-indazolylamino) -6-methylnicotinamide, 2- ( 1H -5-indazolylamino) -6-methyl- N- (3-pyridyl) -nicotinamide, 2- ( 1H -5-indazolylamino) -6-methyl- N- (3-pyridylmethyl) -nicotylamide and 6-methylnicotinamide derivatives and pharmaceutically acceptable salts thereof, which are 2- (1H-5-indazolylamino) -6-methyl- N- (3-pyridylethyl) -nicotylamide. 1) 2-Chloro-6-methylnicotinic acid (2) and 5-aminoindazole (3) were heated in the presence of a base to give 2- ( 1H -5-indazolylamino) -6-methylnicotinic acid (4). Preparing step (step 1); And 2) activating compound (4) prepared in step 1, and then reacting with an amine compound (5) to prepare a 6-methylnicotinamide derivative of formula (1) (6) Method for preparing nicotinamide derivatives. Scheme 1

In Scheme 1, R And n is as defined in formula (1). A pharmaceutical composition for preventing or treating hepatitis B, which comprises the 6-methylnicotinamide derivative of claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient. A pharmaceutical composition for preventing or treating hepatitis C, comprising the 6-methylnicotinamide derivative of claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient. A pharmaceutical composition for preventing or treating AIDS, comprising the 6-methylnicotinamide derivative of claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient.